ReviewClinical pharmacokinetics2017
Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.
Review in Clinical pharmacokinetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- Bioequivalence evaluation of generic febuxostat versus FeburicBMC pharmacology & toxicology · 2025Trial
- Acute effects of hypouricemia on endothelium, oxidative stress, and arterial stiffness: A randomized, double-blind, crossover study.Physiological reports · 2021Trial
- Severe Hypouricemia Impairs Endothelium-Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo-Controlled, and Crossover Study.Journal of the American Heart Association · 2019Trial
- Contribution of Organic Anion Transporter 3 in Delayed Elimination of Methotrexate by Concomitant Administration of Febuxostat.Biopharmaceutics & drug disposition · 2025Article
- An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction.Pharmacology research & perspectives · 2024Article
- Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect.BMC pharmacology & toxicology · 2024Article
- Prediction of drug-drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach.BMC pharmacology & toxicology · 2024Article
- Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat.Cureus · 2023Review
- Development and evaluation of febuxostat solid dispersion through screening method.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice.Pharmaceutics · 2023Article
- Article
- Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout.British journal of clinical pharmacology · 2022Article
- Febuxostat Therapy for Patients with Gout and Stage 2-4 CKD: a Retrospective Study.Rheumatology and therapy · 2022Article
- Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia.The Journal of veterinary medical science · 2022Article
- Non-Immunologic Causes of Late Death-Censored Kidney Graft Failure: A Personalized Approach.Journal of personalized medicine · 2022Review
- High-Throughput mRNA Sequencing Reveals Potential Therapeutic Targets of Febuxostat in Secondary Injury After Intracerebral Hemorrhage.Frontiers in pharmacology · 2022Article
- Honorary Professor Garry Graham.Inflammopharmacology · 2021Article
- Fabrication of ZIF-71/FeRSC advances · 2021Article
- Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.Clinical pharmacokinetics · 2021Article
- Xanthine Oxidoreductase Inhibitors.Handbook of experimental pharmacology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Febuxostat is a xanthine oxidoreductase inhibitor that has been developed to treat chronic gout. In healthy subjects, the pharmacokinetic parameters of febuxostat after multiple oral dose administration include an oral availability of about 85 %, an apparent oral clearance (CL/F) of 10.5 ± 3.4 L/h and an apparent volume of distribution at steady state (V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.